05:30 AM EDT, 04/08/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Tuesday that the latest results from a trial of the investigational nipocalimab plus standard of care administered to adults with generalized myasthenia gravis showed "maintained improvements" over 84 weeks.

The company said results from the additional analyses of its phase 3 study and the ongoing open-label extension evaluating the long-term efficacy and safety of nipocalimab produced "sustained reductions" in total immunoglobulin G.

Up to 128 weeks and 180 patient-years of follow-up in the open-label extensions "confirm a safety profile consistent" with its phase 3 study, Johnson & Johnson ( JNJ ) said.

The nipocalimab plus standard of care group showed four times greater odds of improving and maintaining the strength and function of different muscle groups, compared with placebo plus standard of care in the 24-week double-blind phase of the study.

Myasthenia gravis is a disease in which the immune system mistakenly makes antibodies, potentially blocking or disrupting normal signaling from nerves to muscles.

The company's shares were up 2.8% in recent premarket activity.